Pharmaceuticals

Proteasome Inhibitors Market Expansion Forecast Reaching $3.27 Billion By 2030 At 7.7% CAGR

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Proteasome Inhibitors Market Be By 2030 Compared To Its 2026 Market Size?

The proteasome inhibitors market has experienced robust expansion recently. This market is projected to expand from $2.17 billion in 2025 to $2.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. Historically, this growth can be attributed to the approval of the initial proteasome inhibitors, the increasing prevalence of multiple myeloma, rising investment in oncology research, advancements in cancer diagnostics, and the expansion of hospital oncology departments.

The proteasome inhibitors market is projected to experience substantial expansion over the upcoming years, with its size forecast to reach $3.49 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.2%. This growth in the forecast period is primarily attributed to the broadening of the proteasome inhibitor pipeline, the integration of AI in drug discovery, a rising demand for combination therapies, the development of oral formulations, and the expansion of emerging oncology markets. Significant trends anticipated during this period include personalized cancer therapies, targeted proteasome inhibition, the ongoing development of combination therapies, improved drug delivery systems, and an expansion of clinical trials.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12251&type=smp

Which Drivers Are Supporting The Proteasome Inhibitors Market Growth?

The growing occurrence of pancreatic cancer is projected to boost the expansion of the proteasome inhibitors market moving forward. This malignancy originates in the pancreas, an organ situated in the abdomen behind the stomach. Proteasome inhibitors are chiefly employed in treating pancreatic cancer, as proteasomes significantly contribute to cancer cell survival and proliferation by breaking down proteins that govern cell cycle and apoptosis. These inhibitors impede the survival of cancer cells and restrict tumor development and spread. For example, reports from the American Cancer Society, a US-based health body, indicated in January 2024 that approximately 64,050 adults in the US had been diagnosed with pancreatic cancer by 2023, with 50,550 deaths from the disease. Subsequently, these figures climbed to 66,440 diagnoses and 51,750 deaths. Consequently, the rising incidence of pancreatic cancer is a key factor propelling the expansion of the proteasome inhibitors market.

How Is The Proteasome Inhibitors Market Segmented Across Different Segment Categories?

The proteasome inhibitors market covered in this report is segmented –

1) By Product: Velcade, Kyprolis, Ninlaro, Other Products

2) By Drugs: Bortezomib, Carfilzomib, Ixazomib

3) By Indication: Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospital, Specialty Clinics, Other End-Users

Subsegments:

1) By Velcade: Injectable Velcade (Bortezomib), Oral Formulations

2) By Kyprolis: Injectable Kyprolis (Carfilzomib), Combination Therapies With Kyprolis

3) By Ninlaro: Oral Ninlaro (Ixazomib), Combination Therapies With Ninlaro

4) By Other Products: Investigational Proteasome Inhibitors, Combination Products

What Trends Are Influencing The Evolution Of The Proteasome Inhibitors Market?

Companies operating within the proteasome inhibitors market are concentrating on introducing advanced, pre-prepared formulations to enhance treatment efficacy, simplify clinical administration, and improve patient safety. Ready-to-use injectable products eliminate the necessity for on-site reconstitution, thereby reducing preparation time, minimizing dosing errors, and supporting more streamlined oncology care. For instance, in April 2025, Amneal Pharmaceuticals Inc., a US-based specialty pharmaceutical company, launched BORUZU, the first ready-to-use bortezomib injection indicated for multiple myeloma and mantle cell lymphoma. This formulation is designed to improve clinical workflow by enabling direct administration without reconstitution, assisting healthcare providers in delivering faster and more reliable proteasome inhibitor therapy in outpatient and hospital settings.

Which Organizations Play A Role In The Proteasome Inhibitors Market Landscape?

Major companies operating in the proteasome inhibitors market are Pfizer Inc., Johnson And Johnson, Onyx Pharmaceuticals Inc., Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Apotex Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, AbbVie, Karyopharm Therapeutics, OncoArendi Therapeutics, Novartis AG, GlaxoSmithKline plc, Sanofi S.A., Eli Lilly and Company

Get The Full Proteasome Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report

Where Is The Proteasome Inhibitors Market Most Concentrated Geographically?

North America was the largest region in the proteasome inhibitors market in 2025. The regions covered in the proteasome inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Proteasome Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report

Browse Through More Reports Similar to the Global Proteasome Inhibitors Market 2026, By The Business Research Company

Proteasome Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/proteasome-inhibitors-global-market-report

Proteases Market Report 2026

https://www.thebusinessresearchcompany.com/report/proteases-global-market-report

Serine Proteases Market Report 2026

https://www.thebusinessresearchcompany.com/report/serine-proteases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795